Home > Insider Trading > Filing (0000899140-23-000730)

Filing Details

Accession Number:: 0000899140-23-000730
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-06-07 20:10:19
Reporting Period:: 2023-06-05

Accepted Time:: 2023-06-07 20:10:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1080014	Innoviva Inc.	INVA	Pharmaceutical Preparations (2834)	943265960

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	C/O Sarissa Capital Management Lp 680 Steamboat Road Greenwich CT 06830		No	No	No	No
1577524	Sarissa Capital Management Lp	680 Steamboat Road Greenwich CT 06830		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	Acquisiton	2023-06-05	7,000	$13.04	7,207,000	No	4	P	Indirect	See footnotes
Common Stock, Par Value $0.01 Per Share	Acquisiton	2023-06-06	8,000	$13.05	7,215,000	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

On June 5, 2023, the Reporting Persons acquired 7,000 shares of Common Stock at a weighted average price of $13.0424 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.005 to $13.20 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
On June 6, 2023, the Reporting Persons acquired 8,000 shares of Common Stock at a weighted average price of $13.048 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.04 to $13.09 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions.
Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein.